NanoSiliCal Devices s.r.l

It aims to develop nanostructured products that may be exploited as smart anticancer therapies, basing its activities on the results of experimental studies, gained in the last 10 years, that haveled to several International Patent Applications and publications on international journals with high impact factor. Research and development activities are the aim of the innovative nature of NanoSiliCal Devices. NanoSiliCal Devices produces multi-functional nano-structured systems, based on mesoporous silica (Mesoporous Silica Nanoparticles, MSNs), for the intracellular release of biologically active molecules. MSNs are highly versatile systems, since different kinds of organic ligands can be grafted on the MSNs surface to provide hybrid and multifunctional solutions of high therapeutic interest, which are able to target specific tissues, e.g by selectively directing a drug to cancer cells. NanoSiliCal Devices is the result of several studies based on properties, synthesis, characterization and biological validation of mesoporous silicas. hese studies involve a modular method of synthesis of mesoporous silica based micro-and nano-systems that could be used for drug delivery. Mesoporous silica nanodevices (MSN) bearing a targeting molecule on the outer surface and a specific drug linked within the pores, as vehicles for targeting and release of biologically active molecules, are developed to be employed in targeted therapy. This is an excellent drug delivery system based on Receptor-specific ligand on the external surface and drug inside the pores. The main application of our products is the targeted chemotherapy, whose main purpose is to reduce drug doses, to improve therapeutic efficacy and to reduce toxic and side effects. To this aim, we create and develop new vehicles that could be used in targeted therapy, by releasing antineoplastic drugs directly inside the cancer cells, thus preventing and minimizing their effects on healthy tissues. The administration of antineoplastic drugs produces high toxicity that limits the therapeutic effect and reduces patients adherence to therapy; the use of subtherapeutic doses could cause the development of drug resistance due to biochemical changes or change in the mechanisms of drug elimination and/or uptake. Our Team Who's behind the scenes? Send e-mail